Physician profile
Manu Jain
NPI 1609806249
$187,267.76
in general payments reported to CMS, 2019-2025
9 companies · $5,998 in 2025
The $5,998 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $44K · 2021: $37K · 2022: $21K · 2023: $21K · 2024: $78.63 · 2025: $5,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Travel and Lodging: $2,095 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,740 · Food and Beverage: $1,038 · Education: $34.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,670.00 |
| Travel and Lodging | $2,095.31 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,740.00 |
| Food and Beverage | $1,037.97 |
| Education | $34.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $102,408.44 | 2019-2023 | Veklury, Cayston |
| Vertex Pharmaceuticals Incorporated | $44,665.93 | 2019-2025 | |
| Insmed, INC. | $23,866.16 | 2019-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $13,475.00 | 2020-2023 | |
| Eli Lilly and Company | $1,800.00 | 2021 | |
| Hill-Rom Company, INC | $875.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.68 | 2022 | |
| Philips North America LLC | $68.04 | 2023 | |
| Terumo Medical Corporation | $24.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manu Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.